Anika Therapeutics (ANIK) Tops Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. GOOGL
6. RTX
7. COF
8. SMCI
9. TSLA
10. BRZE

Go back to Anika Therapeutics (ANIK) Tops Q3 EPS by 21c

Anika Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015

October 28, 2015 4:05 PM EDT

Company Achieves 37.5% Year-over-Year Diluted EPS Growth in Quarter

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology, today reported financial results for the third quarter ended September 30, 2015, along with business progress in the period.

Our third quarter sales and profits were driven by strength in end-user demand, which together with continuing pipeline progress, provides a robust foundation for future growth, stated Charles H. Sherwood, Ph.D., President and Chief Executive Officer. Our viscosupplementation... More